

**STATEMENT OF STANDALONE UNAUDITED RESULTS  
FOR THE QUARTER ENDED 30<sup>TH</sup> JUNE 2014**

(₹ in crore)

Particulars	Quarter Ended			Year Ended
	30.06.2014	31.03.2014	30.06.2013	31.03.2014
	Unaudited	Audited	Unaudited	Audited
<b>1. Income from operations</b>				
a) Net Sales/Income from Operations (Net of excise duty)	2401.52	2211.66	2307.73	9111.56
b) Other Operating Income	72.94	93.20	179.18	345.34
<b>Total income from operations (net)</b>	<b>2474.46</b>	<b>2304.86</b>	<b>2486.91</b>	<b>9456.90</b>
<b>2. Expenses</b>				
a) Cost of materials consumed	684.66	813.82	672.90	3145.34
b) Purchases of stock-in-trade	157.03	203.90	138.23	773.40
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	146.21	(42.72)	131.78	(158.12)
d) Employee benefits expense	382.81	332.80	306.96	1284.75
e) Depreciation and amortisation expense	114.24	81.00	78.88	323.61
f) Other expenses	571.22	638.77	563.40	2422.00
<b>Total expenses</b>	<b>2056.17</b>	<b>2027.57</b>	<b>1892.15</b>	<b>7790.98</b>
<b>3. Profit (+)/Loss (-) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>418.29</b>	<b>277.29</b>	<b>594.76</b>	<b>1665.92</b>
<b>4. Other Income</b>	<b>37.28</b>	<b>93.54</b>	<b>69.14</b>	<b>280.28</b>
<b>5. Profit (+)/Loss (-) before finance costs and exceptional items (3+4)</b>	<b>455.57</b>	<b>370.83</b>	<b>663.90</b>	<b>1946.20</b>
<b>6. Finance costs</b>	<b>25.15</b>	<b>25.19</b>	<b>39.03</b>	<b>127.86</b>
<b>7. Profit (+)/Loss (-) before exceptional items and tax (5-6)</b>	<b>430.42</b>	<b>345.64</b>	<b>624.87</b>	<b>1818.34</b>
<b>8. Exceptional Item</b>	-	-	-	-
<b>9. Profit(+)/Loss(-) before tax (7-8)</b>	<b>430.42</b>	<b>345.64</b>	<b>624.87</b>	<b>1818.34</b>
<b>10. Tax expense</b>	<b>98.25</b>	<b>69.00</b>	<b>149.97</b>	<b>430.00</b>
<b>11. Net Profit (+)/Loss (-) after tax (9-10)</b>	<b>332.17</b>	<b>276.64</b>	<b>474.90</b>	<b>1388.34</b>
<b>12. Paid-up equity share capital (Face Value ₹2 per share)</b>	<b>160.58</b>	<b>160.58</b>	<b>160.58</b>	<b>160.58</b>
<b>13. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year</b>				<b>9922.09</b>
<b>14. Earnings per share (₹)</b>				
- Basic	*4.14	*3.44	*5.91	17.29
- Diluted	*4.13	*3.44	*5.91	17.27
*Not Annualised				

Particulars	Quarter Ended			Year Ended
	30.06.2014	31.03.2014	30.06.2013	31.03.2014
<b>A. PARTICULARS OF SHAREHOLDING</b>				
<b>1. Public shareholding</b>				
- Number of shares	<b>498510398</b>	498568383	498844405	498568383
- Percentage of shareholding	<b>62.09</b>	62.09	62.13	62.09
<b>2. Promoters and Promoter Group Shareholding</b>				
a) Pledged/Encumbered				
- Number of shares	<b>NIL</b>	NIL	NIL	NIL
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	<b>NIL</b>	NIL	NIL	NIL
- Percentage of shares (as a % of the total share capital of the company)	<b>NIL</b>	NIL	NIL	NIL
b) Non-Encumbered				
- Number of shares	<b>295485978</b>	295485978	295485978	295485978
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	<b>100.00</b>	100.00	100.00	100.00
- Percentage of shares (as a % of the total share capital of the company)	<b>36.80</b>	36.80	36.80	36.80


Particulars	Quarter Ended 30.06.2014
<b>B. INVESTOR COMPLAINTS</b>	
Pending at the beginning of the quarter	Nil
Received during the quarter	12
Disposed of during the quarter	12
Remaining unresolved at the end of the quarter	Nil

## Notes:

- The Company is essentially in the pharmaceutical business segment.
- In 2003, the Company received notice of demand from the National Pharmaceutical Pricing Authority, Government of India on account of alleged overcharging in respect of certain drugs under the Drugs (Prices Control) Order, 1995. This was contested before the jurisdictional High Courts in Mumbai, Karnataka and Allahabad wherein it was held in favour of the Company. The orders of Hon'ble High Court of Allahabad and Bombay were challenged before the Hon'ble Supreme Court of India by the Government. Although in the challenge to the decision of the Hon'ble Bombay High Court, the Hon'ble Supreme Court of India restored the matter to the Hon'ble Bombay High Court in August 2003 for interpreting the Drug Policy on the basis of directions and principles laid down by them and the same was pending, in the challenge to the Hon'ble High Court of Allahabad's order, in February 2013, the Hon'ble Supreme Court of India transferred the Bombay High Court petition also before itself for a final hearing on both the matters. In an earlier order, the Hon'ble Supreme Court has already restrained the Government from taking any coercive action against the Company. The Company has been legally advised that on the basis of these orders there is no probability of demand crystallising. Hence no provision is considered necessary in respect of notice of demand received by the company up to date aggregating to ₹1768.51 crore.
- During the current quarter, pursuant to the enactment of the Companies Act 2013 (the 'Act'), the Company has, effective 1<sup>st</sup> April 2014, reviewed and revised estimated useful lives of its fixed assets, generally in accordance with the provisions of Schedule II to the Act. In case of any asset whose useful life is already exhausted as on 1<sup>st</sup> April, 2014, the carrying value, net of residual value and deferred tax has been adjusted in retained earnings in accordance with the requirements of Schedule II of the Act. As a result the charge of depreciation is higher by ₹30.41 crore for the quarter ended 30<sup>th</sup> June, 2014.
- The figures for the quarter ended 31<sup>st</sup> March 2014 are the balancing figures between audited figures in respect of the full financial year ended 31<sup>st</sup> March 2014 and the published unaudited figures for the nine months ended 31<sup>st</sup> December 2013.
- The figures of the previous year/periods have been regrouped/ recast to render them comparable with the figures of the current period.

6. The above standalone financial results for the quarter ended 30<sup>th</sup> June 2014 have been subjected to Limited Review by the Statutory Auditors, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14<sup>th</sup> August, 2014.

By order of the Board  
For CIPLA LIMITED



Dr. Y. K. Hamied  
Chairman

Mumbai  
14<sup>th</sup> August, 2014

**R. G. N. Price & Co.**  
Chartered Accountants  
204, Parekh Building,  
N. G. Acharya Marg,  
Chembur,  
Mumbai - 400 071.

**V. Sankar Aiyar & Co.**  
Chartered Accountants  
2-C, Court Chambers,  
35, New Marine Lines  
Mumbai - 400 020.

**The Board of Directors**  
**Cipla Ltd.**  
Lower Parel,  
Mumbai - 400 013.

*Dear Sirs,*


**Re : Limited Review Report on the Unaudited Standalone Financial Results for the quarter ended June 30, 2014**

#### **Introduction**

We have reviewed the accompanying statement of unaudited standalone financial results ("financial results") of **M/s. Cipla Limited** ('the Company') for the quarter ended June 30, 2014, except for the disclosures regarding 'Public Shareholding' and 'Promoters and Promoter Group Shareholding' which have been traced from disclosures made by the Management and have not been audited by us. These financial results are the responsibility of the Company's Management and have been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.

#### **Scope of Review**


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



## Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared for the quarter ended June 30, 2014 in accordance with the applicable accounting standards notified pursuant to Companies (Accounting Standards) Rules, 2006 which continue to apply as per Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014, and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R.G.N. Price & Co.  
Chartered Accountants  
Firm Registration No. 002785S



R. Rangarajan  
(Partner)  
Membership No. 41883


Place : Mumbai  
Date : 14<sup>th</sup> August 2014



For V. Sankar Aiyar & Co.  
Chartered Accountants  
Firm Registration No. 109208W



V. Mohan  
(Partner)  
Membership No. 17748



STATEMENT OF CONSOLIDATED UNAUDITED RESULTS  
FOR THE QUARTER ENDED 30<sup>TH</sup> JUNE 2014

(₹ in crore)

Particulars	Quarter Ended			Year Ended
	30.06.2014	31.03.2014	30.06.2013	31.03.2014
	Unaudited	Audited	Unaudited	Audited
<b>1. Income from operations</b>	<b>2647.20</b>	<b>2445.33</b>	<b>2331.22</b>	<b>9825.80</b>
a) Net Sales/Income from Operations (Net of excise duty)				
b) Other Operating Income	72.80	90.24	180.19	347.59
<b>Total income from operations (net)</b>	<b>2720.00</b>	<b>2535.57</b>	<b>2511.41</b>	<b>10173.39</b>
<b>2. Expenses</b>				
a) Cost of materials consumed	735.57	949.27	685.24	3376.22
b) Purchases of stock-in-trade	134.76	61.88	102.34	562.86
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	154.89	(7.61)	130.55	(64.25)
d) Employee benefits expense	479.98	427.93	329.20	1542.96
e) Depreciation and amortisation expense	125.40	105.01	85.03	372.64
f) Other expenses	673.02	694.82	574.43	2622.55
<b>Total expenses</b>	<b>2303.62</b>	<b>2231.30</b>	<b>1906.79</b>	<b>8412.98</b>
<b>3. Profit (+)/Loss (-) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>416.38</b>	<b>304.27</b>	<b>604.62</b>	<b>1760.41</b>
<b>4. Other Income</b>	<b>40.39</b>	<b>77.52</b>	<b>68.69</b>	<b>265.37</b>
<b>5. Profit (+)/Loss (-) before finance costs and exceptional items (3+4)</b>	<b>456.77</b>	<b>381.79</b>	<b>673.31</b>	<b>2025.78</b>
<b>6. Finance costs</b>	<b>33.32</b>	<b>34.11</b>	<b>39.57</b>	<b>145.74</b>
<b>7. Profit (+)/Loss (-) before exceptional Items and tax (5-6)</b>	<b>423.45</b>	<b>347.68</b>	<b>633.74</b>	<b>1880.04</b>
<b>8. Exceptional Item</b>	-	-	-	-
<b>9. Profit(+)/Loss(-) before tax (7-8)</b>	<b>423.45</b>	<b>347.68</b>	<b>633.74</b>	<b>1880.04</b>
<b>10. Tax expense</b>	<b>101.88</b>	<b>75.30</b>	<b>153.62</b>	<b>463.38</b>
<b>11. Net Profit (+)/Loss (-) after tax (9-10)</b>	<b>321.57</b>	<b>272.38</b>	<b>480.12</b>	<b>1416.66</b>
<b>12. Share of Profit (+) / Loss (-) of associates</b>	<b>(18.11)</b>	<b>(3.10)</b>	<b>5.23</b>	<b>(12.32)</b>
<b>13. Minority Interest</b>	<b>8.88</b>	<b>8.59</b>	-	<b>15.93</b>
<b>14. Net Profit (+) / Loss (-) after minority interest and share of profit/loss of associates (11+12-13)</b>	<b>294.58</b>	<b>260.69</b>	<b>485.35</b>	<b>1388.41</b>
<b>15. Paid-up equity share capital (Face Value ₹2 per share)</b>	<b>160.58</b>	<b>160.58</b>	<b>160.58</b>	<b>160.58</b>
<b>16. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year</b>				<b>9880.80</b>
<b>17. Earnings per share (₹)</b>				
- Basic	*3.67	*3.25	*6.04	17.29
- Diluted	*3.66	*3.24	*6.04	17.27
*Not Annualised				

Particulars	Quarter Ended			Year Ended
	30.06.2014	31.03.2014	30.06.2013	31.03.2014
<b>A. PARTICULARS OF SHAREHOLDING</b>				
<b>1. Public shareholding</b>				
- Number of shares	<b>498510398</b>	498568383	498844405	498568383
- Percentage of shareholding	<b>62.09</b>	62.09	62.13	62.09
<b>2. Promoters and Promoter Group Shareholding</b>				
a) Pledged/Encumbered				
- Number of shares	<b>NIL</b>	NIL	NIL	NIL
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	<b>NIL</b>	NIL	NIL	NIL
- Percentage of shares (as a % of the total share capital of the company)	<b>NIL</b>	NIL	NIL	NIL
b) Non-Encumbered				
- Number of shares	<b>295485978</b>	295485978	295485978	295485978
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	<b>100.00</b>	100.00	100.00	100.00
- Percentage of shares (as a % of the total share capital of the company)	<b>36.80</b>	36.80	36.80	36.80

Particulars	Quarter Ended 30.06.2014
<b>B. INVESTOR COMPLAINTS</b>	
Pending at the beginning of the quarter	Nil
Received during the quarter	12
Disposed of during the quarter	12
Remaining unresolved at the end of the quarter	Nil

## Notes:

- The Company is essentially in the pharmaceutical business segment.
- The consolidated accounts have been prepared in accordance with the principles set out in Accounting Standard 21 - Consolidated Financial Statements, Accounting Standard 23 - Accounting for Investments in Associates and Accounting Standard 27 - Financial Reporting in Joint Ventures in Consolidated Financial Statements notified in the Companies (Accounting Standard) Rules, 2006. The financial results of associates and joint venture have been included in the consolidated results on the basis of management accounts not reviewed by the auditors.
- In 2003, the Company received notice of demand from the National Pharmaceutical Pricing Authority, Government of India on account of alleged overcharging in respect of certain drugs under the Drugs (Prices Control) Order, 1995. This was contested before the jurisdictional High Courts in Mumbai, Karnataka and Allahabad wherein it was held in favour of the Company. The orders of Hon'ble High Court of Allahabad and Bombay were challenged before the Hon'ble Supreme Court of India by the Government. Although in the challenge to the decision of the Hon'ble Bombay High Court, the Hon'ble Supreme Court of India restored the matter to the Hon'ble Bombay High Court in August 2003 for interpreting the Drug Policy on the basis of directions and principles laid down by them and the same was pending, in the challenge to the Hon'ble High Court of Allahabad's order, in February 2013, the Hon'ble Supreme Court of India transferred the Bombay High Court petition also before itself for a final hearing on both the matters. In an earlier order, the Hon'ble Supreme Court has already restrained the Government from taking any coercive action against the Company. The Company has been legally advised that on the basis of these orders there is no probability of demand crystallising. Hence no provision is considered necessary in respect of notice of demand received by the company up to date aggregating to ₹1768.51 crore.
- During the current quarter, pursuant to the enactment of the Companies Act 2013 (the 'Act'), the Company has, effective 1<sup>st</sup> April 2014, reviewed and revised estimated useful lives of its fixed assets, generally in accordance with the provisions of Schedule II to the Act. In case of any asset whose useful life is already exhausted as on 1<sup>st</sup> April, 2014, the carrying value, net of residual value and deferred tax has been adjusted in retained earnings in accordance with the requirements of Schedule II of the Act. As a result the charge of depreciation in standalone financial results is higher by ₹ 30.41 crore for the quarter ended 30<sup>th</sup> June 2014. However in case of Indian subsidiaries the consequential impact (after considering the transition provision specified in Schedule II) on the depreciation charged and on the results for the quarter is not material.

5. The Unaudited Standalone financial results for the quarter ended 30<sup>th</sup> June 2014 is available on the Company's website i.e. www.cipla.com and on the Stock Exchange's website: www.bseindia.com and www.nseindia.com. The key standalone financial information are as under:

(₹ in crore)

Particulars	Quarter Ended			Year Ended
	30.06.2014	31.03.2014	30.06.2013	31.03.2014
	Unaudited	Audited	Unaudited	Audited
Total income from operations (net)	2474.46	2304.86	2486.91	9456.90
Profit before tax	430.42	345.64	624.87	1818.34
Profit after tax	332.17	276.64	474.90	1388.34

6. The figures for the quarter ended 31<sup>st</sup> March 2014 are the balancing figures between audited figures in respect of the full financial year ended 31<sup>st</sup> March 2014 and the published unaudited figures for the nine months ended 31<sup>st</sup> December 2013.
7. The figures of the previous year/periods have been regrouped/ recast to render them comparable with the figures of the current period.
8. The above consolidated financial results for the quarter ended 30<sup>th</sup> June, 2014 have been subjected to Limited Review by the Statutory Auditors, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14<sup>th</sup> August, 2014.

By order of the Board  
For CIPLA LIMITED



Dr. Y. K. Hamied  
Chairman

Mumbai  
14<sup>th</sup> August, 2014



**R. G. N. Price & Co.**  
Chartered Accountants  
204, Parekh Building,  
N. G. Acharya Marg,  
Chembur,  
Mumbai - 400 071.

**V. Sankar Aiyar & Co.**  
Chartered Accountants  
2-C, Court Chambers,  
35, New Marine Lines  
Mumbai - 400 020.

**The Board of Directors**  
**Cipla Ltd.**  
Lower Parel,  
Mumbai - 400 013.

*Dear Sirs,*

**Re : Limited Review Report on the Unaudited Consolidated Financial Results for the quarter ended June 30, 2014.**


#### **Introduction**

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results ('the Statement') of **M/s. Cipla Limited** ('the Company'), its subsidiaries, associates and Joint venture (collectively known as "the Group") for the quarter ended June 30, 2014 except for the disclosures regarding 'Public Shareholding' and 'Promoters and Promoter Group Shareholding' which have been traced from disclosures made by the Management and have not been audited by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

#### **Scope of Review**

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The financial results of 4 subsidiaries whose financial results reflects total revenue of Rs. 63.75 crores and the net profit after tax of Rs. 2.73 crores for the quarter ended June 30, 2014 have been reviewed by one of us.



The financial results of 18 Subsidiaries whose financial results reflect total revenue of Rs. 126.59 crores and the net loss after tax of Rs. 10.44 crores for the quarter ended June 30, 2014 and in respect of 1 Joint Venture Company whose financial results reflect total revenue of Rs Nil and net profit of Rs. Nil for the quarter ended June 30, 2014, have not been reviewed by their auditors. These financial results have been certified by the Company's management and furnished to us, and our review, in so far as it relates to the amount included in respect of those 18 Subsidiaries and 1 Joint venture company, are based solely on the Management certified financial results.


Further, the financial results of 28 Subsidiaries incorporated outside India as drawn up in accordance with the generally accepted accounting principles of the respective countries (Local GAAP) have been reviewed by other auditors, duly qualified to act as auditor in those countries, whose financial results reflects total revenue of Rs. 327.40 crores and the net profit after tax and minority interest of Rs.13.34 crores for the quarter ended June 30, 2014. The aforesaid local GAAP financial results have been restated by the management so that they conform to the generally accepted accounting principles in India. Our review on the statement, insofar as it relates to these entities, is based on the aforesaid review reports of those other Auditors.

Further, the financial results of 4 Associates whose share of loss of Rs. 18.11 crores for the quarter ended June 30, 2014 have not been reviewed by their auditors. These financial results have been certified by the Company's management and furnished to us, and our review, in so far as it relates to the amount included in respect of the 4 Associates are based solely on these certified financial results.

#### Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared for the quarter ended June 30, 2014 in accordance with the applicable accounting standards notified pursuant to Companies (Accounting Standards) Rules, 2006 which continue to apply as per Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014, and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.


For R.G.N. Price & Co.  
Chartered Accountants  
Firm Registration No. 002785S

  
R. Rangarajan  
(Partner)  
Membership No. 41883

Place : Mumbai  
Date : 14<sup>th</sup> August 2014



For V. Sankar Aiyar & Co.  
Chartered Accountants  
Firm Registration No. 109208W

  
V. Mohan  
(Partner)  
Membership No. 17748

